Log in
Enquire now
‌

US Patent 9018161 Protease resistant insulin analogues

Patent 9018161 was granted and assigned to Novo Nordisk on April, 2015 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Novo Nordisk
Novo Nordisk
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9018161
Date of Patent
April 28, 2015
Patent Application Number
12442190
Date Filed
September 20, 2007
Patent Citations Received
‌
US Patent 11752216 Insulin analog complex with reduced affinity for insulin receptor and use thereof
‌
US Patent 12059452 Fusion proteins
0
Patent Primary Examiner
‌
Christina Bradley
Patent abstract

The present invention relates to novel insulin analogues exhibiting resistance towards protease, wherein at least two amino acids are substituted and/or deleted relative to the parent insulin molecule. A method for the preparation of such insulin analogues, insulin preparations containing the insulin analogues of the invention and a method of treating diabetes mellitus using these insulin analogues is also provided.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9018161 Protease resistant insulin analogues

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.